An article in The Guardian by Hannah Devlin on our HEART study looking at polygenic risk scores for the prevention of common diseases like cardiovascular disease.

Companies confirm a two-year extension of their collaboration using genomics and machine learning to identify novel targets for innovative medicines and accelerate drug discovery

The NHS and UK biotech company Genomics plc have announced a pilot study that aims to more accurately predict patients’ risk of heart disease using a new integrated polygenic and clinical risk tool.

• Polygenic risk scores (PRS) substantially enhance risk prediction in cardiovascular disease (CVD), the #1 cause of death around the world
• These study results represent the first clinical validation of such a tool across multiple ancestries and ethnicities

An article in The Guardian by Hannah Devlin on our HEART study looking at polygenic risk scores for the prevention of common diseases like cardiovascular disease.

Companies confirm a two-year extension of their collaboration using genomics and machine learning to identify novel targets for innovative medicines and accelerate drug discovery

The NHS and UK biotech company Genomics plc have announced a pilot study that aims to more accurately predict patients’ risk of heart disease using a new integrated polygenic and clinical risk tool.

• Polygenic risk scores (PRS) substantially enhance risk prediction in cardiovascular disease (CVD), the #1 cause of death around the world
• These study results represent the first clinical validation of such a tool across multiple ancestries and ethnicities

An article in The Guardian by Hannah Devlin on our HEART study looking at polygenic risk scores for the prevention of common diseases like cardiovascular disease.

Companies confirm a two-year extension of their collaboration using genomics and machine learning to identify novel targets for innovative medicines and accelerate drug discovery

The NHS and UK biotech company Genomics plc have announced a pilot study that aims to more accurately predict patients’ risk of heart disease using a new integrated polygenic and clinical risk tool.

• Polygenic risk scores (PRS) substantially enhance risk prediction in cardiovascular disease (CVD), the #1 cause of death around the world
• These study results represent the first clinical validation of such a tool across multiple ancestries and ethnicities